

12 **EUROPEAN PATENT APPLICATION**

21 Application number: 90303130.0

51 Int. Cl.⁵ **A61K 9/14, A61K 31/505,**
A61K 31/525, A61K 47/26

22 Date of filing: 23.03.90

30 Priority: 29.03.89 JP 79076/89

43 Date of publication of application:
03.10.90 Bulletin 90/40

84 Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

71 Applicant: **TAKEDA CHEMICAL INDUSTRIES,**
LTD.
3-6, Doshomachi 2-chome Chuo-ku
Osaka 541(JP)

72 Inventor: **Izuhara, Selji**
330-103, 2 Teraikedai 4-chome
Tondabayashi Osaka 584(JP)
Inventor: **Kakiguchi, Yoshitomi**
183-20, Aza-kannonji, Yato
Kawanishi, Hyogo 666-01(JP)
Inventor: **Yokota, Kunihiko**
D75-208, 11 Tsukumodal 5-chome
Suita, Osaka 565(JP)

74 Representative: **Lewin, John Harvey et al**
ELKINGTON AND FIFE Beacon House 113
Kingsway
London WC2B 6PP(GB)

54 **Vitamin B group compound composition and its production.**

57 A composition which consists essentially of a compound belonging to the Vitamin B group and having a solubility in water of not more than 5% and mannitol, is stable in itself and undergoes less influence under ambient humidity conditions.

Its good flowability is retained during storage, only with very small changes, if any.

EP 0 390 435 A1

Vitamin B group compound composition and its production.

FIELD OF THE INVENTION

This invention relates to a vitamin B group compound composition which has good stability and flowability and can advantageously be used in the food, pharmaceutical and feed industries. among others, in the manufacture of such dosage forms as powders, fine granules, capsules, pills, tablets and pellets.

BACKGROUND OF THE INVENTION

Vitamin B group compounds, such as folic acid and vitamin B₂, are incorporated in various food, pharmaceutical, feed and other compositions generally at low addition levels. Therefore, it is particularly required that such compounds be distributed uniformly in said compositions. In particular, the levels of addition of folic acid and vitamin B₂ are low in most instances. However, since they occur as fine crystalline powders having a high specific volume and showing a strong tendency toward aggregation, their flowability and handling properties are poor and unsatisfactory. Therefore, for preparing homogeneous compositions, a preliminary dilution step is generally employed in which they are diluted 10-, 100- or 1,000-fold, for instance, with starch, alpha-starch, lactose or some other appropriate excipient.

A method of obtaining free-flowing powders that has already been provided comprises contacting with a spray jet of a superfine absorbent powder and effecting spray drying (Japanese Patent Application KOKAI No. 49-7415). However, the superfine absorbent to be used is an inorganic material unsuited for pharmaceutical purposes. In addition, the method fails to give compositions containing folic acid or vitamin B₂ in high concentrations.

Another method that has been provided for preparing a vitamin B₂ composition capable of being directly submitted to tableting (Japanese Patent Application KOKAI No. 62-174013) gives granules on fluidized bed granulation using a macromolecular compound, such as water-soluble cellulose, as a binding agent. However, this method can hardly be applied to the manufacture of pharmaceutical preparations which should contain vitamin B₂ in very low concentrations, for instance.

In some of the prior art compositions, the proportion of the excipient is too high for incorporation of other active ingredients into the compositions, while in others the excipient itself is unsuited for pharmaceutical preparations. These are the problems that remain to be solved.

Accordingly, the advent of a composition which contains a vitamin B group compound, such as folic acid or vitamin B₂, has a low excipient content, has good flowability but no tendency toward aggregation, and can be used in the manufacture of pharmaceutical preparations is desired.

SUMMARY OF THE INVENTION

The present inventors found that a vitamin B group compound composition which is safe, has good flowability and can be readily incorporated into various formulations can be obtained by uniformly suspending a vitamin B group compound in an aqueous solution of mannitol and subjecting the resulting suspension to spray drying.

They further found that said composition can be converted to a more stable granular powder composition by coating the same with a wax, an oil or fat. The present invention has been completed based on these findings.

DETAILED DESCRIPTION OF THE INVENTION

The invention thus provides a composition which consists essentially of a compound belonging to the vitamin B group and having a solubility in water of not more than 5% and mannitol, and a method of producing such composition.

Any commercially available grade of mannitol can be used in the practice of the invention. Since mannitol is listed in the Japanese Pharmacopeia, the composition according to the invention can be used for pharmaceutical purposes.

The invention is applicable to the following vitamin B group compounds, among others: folic acid, vitamin B₂, riboflavin butyrate ester, biotin, thiamine mononitrate, dibenzoylthiamine, dibenzoylthiamine hydrochloride, thiamine acetylsulfate, thiamine laurylsulfate, thiamine naphthaline-2,6-disulfonate, thiamine naphthaline-1,5-disulfonate, pyridoxine-3,4'-dioctanoate, pyridoxine-3,4'-dipalmitate, pyridoxine-3,4'-dilaurate and pyridoxine-3,4'-dilaurate hydrochloride.

These have a solubility in water at 20°C of not more than 5% (weight/volume), preferably not more than 3%, more preferably not more than 1%.

The vitamin B group compound content in the composition according to the invention is generally within the range of 100 to 5,000 parts by weight, preferably 200 to 3,000 parts by weight, more preferably 400 to 2000 parts by weight per 100 parts by weight of mannitol.

In cases where the content of the vitamin B group compound, such as folic acid or vitamin B₂, exceeds 5,000 parts by weight per 100 parts by weight of mannitol, the granular composition obtained may readily be disintegrated. Where the vitamin B group compound content is below 100 parts by weight per 100 parts by weight of mannitol, the high excipient (mannitol) content may lead to an excessively high mannitol proportion in final preparations manufactured by admixing the composition with another or other active ingredients. That large quantity of mannitol, which is voluminous, may cause troubles in preparing such compositions as tablets.

The composition according to the invention can be produced, for example, in the following manner.

An aqueous solution of mannitol is prepared by dissolving mannitol in distilled water. A vitamin B group compound is added to this solution and uniformly dispersed therein by means of a homomixer. The resulting suspension is then subjected to spray drying using a spray drier. Since the vitamin B group compound to be used in the practice of the invention has a solubility in water of not more than 5%, said compound remains in a suspended state in the aqueous solution of mannitol.

The aqueous solution of mannitol to be used should have a mannitol concentration of not less than 0.5% (weight/volume). Said concentration should appropriately be selected depending on such factors as the kind and amount of the vitamin B group compound to be contained in the composition to be prepared.

The composition obtained by spray drying generally occurs as a powder which is considerably uniform in composition. The drying is performed at a drying temperature within the range of about 100-180°C, preferably 130-160°C, while the disk is rotated at a rate within the range of about 1,000-30,000 rpm (revolutions per minute), preferably 5,000-20,000 rpm.

The composition according to the invention may be coated with a wax, an oil or fat, which is used in an amount within the range of 0.1 to 50% by weight, preferably 5 to 30% by weight, based on said composition.

As examples of the wax, fat or oil which are usable in the practice of the invention, there may be mentioned carnauba wax, paraffins, stearic acid, white beeswax, macrogols, glycerol fatty acid esters, and various hardened fats and oils (cottonseed oil, soybean oil, palm oil, corn oil, sunflower oil, rapeseed oil, lard, beef tallow, etc.), among others.

While it is a primary object of the invention to provide a composition which comprises a single vitamin B group compound and mannitol, the invention can also provide, in another aspect thereof, a composition which contains two or more vitamin B group compounds and mannitol.

As compared with the conventional compositions in which lactose, starch or the like is used, the composition according to the invention is stable in itself and undergoes less influence under ambient humidity conditions. Therefore, its good flowability is retained during storage, only with very small changes, if any. Furthermore, the composition coated with a wax, a fat or oil exerts little influence on another or other active ingredients when it is admixed with these, whereby the stability of the resulting combination composition itself is improved as well.

Since it is sufficient to use only a small amount of mannitol as an excipient in the composition according to the invention, such operations as weighing and mixing can be rationalized in the manufacture of tablets, capsules, powders, granules, pellets and other preparations.

Furthermore, since the composition according to the invention is small and uniform in grain size, it can be used for low addition level incorporation of a vitamin B group compound or compounds. The invention is particularly effective in cases where folic acid or vitamin B₂ is used; there, the invention affords a composition having good handling characteristics that have never been attained in the prior art.

The following examples illustrate the invention in further detail.

The ingredient materials used all occurred as powders. The sieve mesh designations are based on the Japanese Industrial Standard definition (JIS K 6900).

EP 0 390 435 A1

Example 1 [The powder composition consisting of folic acid and mannitol]

Folic acid was obtained from Takeda Chemical Industries and mannitol from Imperial Chemical Industries (I.C.I.).

5 Folic acid (95 g) was added to a solution of 5 g of mannitol in 200 ml of distilled water and homogeneously dispersed therein by means of a homomixer (T.K. homomixer model M, manufactured by Tokushu Kika Kogyo Comp.).

This folic acid suspension was subjected to spray drying using a mobile minor type spray drier (Ashizawa-Niro Atomizer LTD.) while the homogeneity of said suspension was maintained by stirring. The drying temperature was 150 °C and the disk was rotated at 20,000 rpm.

The thus-obtained composition occurred as a yellow powder. Particle size distribution and repose angle of the composition.

15

(1) Particle size distribution	
Particle size	Proportion
Plus 100-mesh sieve	7.9%
Minus 330-mesh sieve	3.9%

20

25 (2) Repose angle: 42°.

Example 2 [The powder composition consisting of vitamin B₂ and mannitol]

Vitamin B₂ was obtained from Hoffmann-La Roche Inc. and mannitol from I.C.I.

30 Vitamin B₂ (90 g) was added to a solution of 10 g of mannitol in 200 ml of distilled water and homogeneously dispersed therein by means of a homomixer (T.K. homomixer model M, manufactured by Tokushu Kika Kogyo Comp.).

This vitamin B₂ suspension was subjected to spray drying using a mobile minor type spray drier (Ashizawa-Niro Atomizer LTD.) while the homogeneity of the suspension was maintained by stirring. The drying temperature was 150 °C and the disk was rotated at 20,000 rpm.

35 The thus-obtained composition occurred as a yellow powder. Particle size distribution and repose angle of the composition.

40

(1) Particle size distribution	
Particle size	Proportion
Plus 100-mesh sieve	2.3%
Minus 330-mesh sieve	5.7%

45

50 (2) Repose angle: 40°.

Example 3 [Wax-coated powder composition consisting of folic acid and mannitol]

55 The powdery composition consisting of folic acid and mannitol obtained in Example 1 was wax-coated by the hot hexane method. Carnauba wax was used as the wax.

Thus, in a tightly closable container, 0.5 g of carnauba wax was dissolved in 100 ml of hexane warmed to about 75 °C. and 10 g of the powder composition was added to the solution with stirring by means of a

EP 0 390 435 A1

stirrer. The resultant mixture was then allowed to cool to room temperature with the container tightly closed. Thereafter the mixture was filtered through a filter paper. The residue on the filter paper was dried at 40 ° C under vacuum to give a wax-coated powder composition consisting of folic acid and mannitol.

5

Example 4 [The powder composition consisting of folic acid and mannitol]

Folic acid was obtained from Takeda Chemical Industries and mannitol from I.C.I.

10 Folic acid (90 g) was added to a solution of 10 g mannitol in 200 ml of distilled water and homogeneously dispersed therein with a homomixer (T.K. homomixer model M, manufactured by Tokushu Kika Kogyo Comp.).

This folic acid suspension was subjected to spray drying using a mobile minor type spray drier (Ashizawa-Niro Atomizer LTD.) while homogeneity of the suspension was maintained by stirring. The drying temperature was 150 ° C and the disk was rotated at 20,000 rpm.

15 The thus-obtained dry composition occurred as a yellow powder. Particle size distribution and repose angle of the composition

20

(1) Particle size distribution	
Particle size	Proportion
Plus 100-mesh sieve	8.1%
Minus 330-mesh sieve	3.3%

25

(2) Repose angle: 41 ° .

30

Example 5 [The powder composition consisting of vitamin B₂ and mannitol]

Vitamin B₂ was obtained from Hoffmann-La Roche Inc. and mannitol from I.C.I.

35 Vitamin B₂ (97 g) was added to a solution of 3 g of mannitol in 200 ml of distilled water and homogeneously dispersed therein by means of a homomixer (T.K. homomixer model M, manufactured by Tokushu Kika Kogyo Comp.).

This vitamin B₂ suspension was subjected to spray drying using a mobile minor type spray drier (Ashizawa-Niro Atomizer LTD.) while the homogeneity of the suspension was maintained by stirring. The drying temperature was 150 ° C and the disk was rotated at 20,000 rpm.

40 The thus-obtained composition occurred as a yellow powder. Particle size distribution and repose angle of the composition.

45

(1) Particle size distribution	
Particle size	Proportion
Plus 100-mesh sieve	1.0%
Minus 330-mesh sieve	10.7%

50

(2) Repose angle: 42.2 ° .

55

Test method 1 [Folic acid assay]

EP 0 390 435 A1

In the experimental examples, the folic acid assay procedure was performed using light-impermeable containers and avoiding direct sunlight. Assay preparations were prepared by extracting 50 mg of a sample with 20 ml of a dichloromethane-1 N aqueous ammonia mixture (1:1) and subjected to assay by the USP (U.S. Pharmacopeia) method (high-performance liquid chromatography).

Test method 2 [Vitamin B₂ assay]

In the experimental examples, the vitamin B₂ assay procedure was performed using light-impermeable containers and avoiding direct sunlight. Assay preparations were prepared by extracting 30 mg of a sample with 50 ml of 5 N acetic acid and subjected to assay by the USP method (colorimetry).

Test method 3 [Flowability evaluation (measurement of repose angle)]

In the experimental examples, the compositions containing folic acid or vitamin B₂ were evaluated for their flowability as follows: Fifty-five-gram portions of each sample composition were placed in amber-glass desiccators respectively conditioned to 11%, 20%, 31%, 43%, 53%, 68%, 75%, 82% and 91% and, after 2 weeks of storing at 40 °C, repose angle measurements were performed using a Konishi model FK repose angle measuring apparatus (Konishi Medical & Surgical Co.).

Experimental Example 1 [Stability and repose angle data for a folic acid composition and a vitamin B₂ composition]

(After 2 weeks of storage at 40 °C)				
Storage condition	Folic acid composition		Vitamin B ₂ composition	
(Relative humidity)	Content	Repose angle	Content	Repose angle
Initial	100%	41°	100%	40°
11	100	40	99.8	42
20	99.5	40	100	40
31	99.7	41	100	40
43	99.5	41	99.9	40
53	99.3	40	99.7	41
68	99.5	41	100	42
75	99.2	41	99.7	40
82	99	42	100	41
91	98.5	42	100	40
Contents: Expressed in terms of residual percentage.				

As is evident from the data given in the above table, the folic acid composition and vitamin B₂ composition obtained in Example 1 and Example 2, respectively, did not suffer any substantial flowability losses during 2 weeks of storage at 40 °C under various humidity conditions ranging from the highest 91% relative humidity to the lowest 11% relative humidity. The compositions retained their respective active ingredient contents stably.

Experimental Example 2 [Stability of folic acid in a premix]

The wax-coated composition obtained in Example 3 was packed in the form of a premix into a glass bottle and stored airtightly therein under the conditions specified in the table given below, followed by folic acid assay and residual percentage calculation.

Folic acid residual percentage		
Storage conditions	Composition of Example 3	Folic acid bulk substance
40 ° C, 1 month	98%	70%

As the data in the above table indicate, the wax-coated folic acid composition obtained by the method of the invention was more stable than the folic acid bulk substance used as a control.

The premix used was prepared according to the following formula (folic acid content = 100 mg/kg of premix):

Ingredient	Content (per kg)
Vitamin A	1,250,000 IU
Vitamin D	125,000 IU
dl- α -tocopheryl acetate	7.5 g
Phytonadione	0.013 g
Vitamin B ₁	0.5 g
Vitamin B ₂	0.45 g
Vitamin B ₆	0.5 g
Vitamin B ₁₂	0.01 g
Biotin	0.001 g
Calcium D-pantothenate	3.0 g
Nicotinamide	5.0 g
Choline chloride	5.0 g
Manganese (manganese carbonate)	1.0 g
Iron (iron sulfate)	4.5 g
Calcium phosphate	30.0 g
Copper (dried copper sulfate)	0.5 g
Zinc (zinc carbonate)	3.75 g
Iodine (calcium iodate)	0.0375 g
Others (lactose, corn starch, etc.)	Quantity sufficient to make the whole quantity 1 kg

Experimental Example 3 [Flowability of a folic acid composition and of a vitamin B₂ composition]

The folic acid composition obtained in Example 4 and the vitamin B₂ composition obtained in Example 2 as well as folic acid compositions and vitamin B₂ compositions containing the conventional excipient lactose or corn starch were subjected to flowability and stability testing for investigating possible influences of the humidity during storage on the flowability and stability of each composition.

Each composition was allowed to stand at 40 ° C for 2 weeks under the respective humidity conditions (11% to 91% relative humidity) specified in the two tables given below, followed by water content determinations and repose angle measurements.

The compositions used for comparison were as follows:

EP 0 390 435 A1

	(Folic acid)	
	10% Lactose:	
5	Lactose	10 g
	Folic acid	90 g
	10% Corn starch:	
10	Corn starch	10 g
	Folic acid	90 g
	(Vitamin B ₂)	
	10% Lactose:	
15	Lactose	10 g
	Vitamin B ₂	90 g
	10% Corn starch:	
20	Corn starch	10 g
	Vitamin B ₂	90 g

The above compositions for comparison were prepared by the same spray drying method as used in Examples 1 to 3 and submitted to measurements.

25 A 2-gram portion of the samples containing of folic acid stored at a temperature of 40° C for 2 weeks under the specified humidity conditions (11% to 91 % relative humidity) was assayed for water content by the Karl-Fischer method and the increase or decrease in water content was calculated relative to the initial value.

30 A 0.5-gram portion of the samples containing of vitamin B₂ stored at a temperature of 40° C for 2 weeks under the specified humidity conditions (11% to 91% relative humidity) was heated at a temperature of 105° for 2 to 3 hours, and the increase or decrease in water content was calculated relative to the initial value.

35 The repose angle measurement was performed with a 100-gram portion each of the samples stored at a temperature of 40° C for 2 weeks under the specified humidity conditions (11% to 91% relative humidity) using a Konishi model FK angle-of-repose measuring apparatus (Konishi Medical & Surgical Co.). The samples were further evaluated for their flowability by the eye. The measurement and evaluation results were expressed in terms of (+),(-) and (±).

40

45

50

55

Influences of humidity during storage
(folic acid composition)

5

10

15

20

25

30

35

40

45

50

Relative humidity during storage (%)	10% Lactose	10% Corn starch	10% Mannitol
91	+	+	+
	(0.96%)	(0.54%)	(0.66%)
82	+	±	±
	(0.69%)	(0.46%)	(0.50%)
75	+	±	-
	(0.39%)	(0.33%)	(0.40%)
68	+	±	-
	(0.33%)	(0.36%)	(0.40%)
53	+	±	-
	(0.17%)	(0.14%)	(0.31%)
43	±	-	-
	(-0.16%)	(0.07%)	(0.27%)
31	±	-	-
	(0.44%)	(-0.02%)	(0.17%)
20	-	-	-
	(0.16%)	(-0.10%)	(0.07%)
11	-	-	-
	(0 %)	(-0.29%)	(-0.01%)

Repose angle: (-) for 40-45°C, (±) for 45-50°,
(+) for > 50°.

55

Each data in the parentheses (lower row):

Increase or decrease in water content
relative to the initial value.

Influences of humidity during storage
(vitamin B₂ composition)

Relative humidity during storage (%)	10% Lactose	10% Corn starch	10% Mannitol
91	+ (1.11%)		+ (0.13%)
82	+ (0.18%)	+ (1.17%)	- (0.80%)
75	+ (0.11%)	± (0.93%)	- (0.028%)
68	± (-0.01%)	± (0.80%)	- (0.029%)
53	± (-0.16%)	± (0.57%)	- (0.028%)
43	± (-0.17%)	- (0.40%)	- (0.028%)
31	- (0.23%)	- (0.22%)	- (0.01%)
20	- (0.08%)	- (0.01%)	- (-0.09%)
11	- (-0.13%)	- (-0.24%)	- (-0.09%)

Repose angle: (-) for 40-45°C, (±) for 45-50°,
(+) for > 50°.

Each data in the parentheses (lower row):

Increase or decrease in water content
relative to the initial value.

The data shown in the above two tables have revealed that the compositions according to the invention in which mannitol is used show higher stability and less flowability losses during storage as compared with the compositions in which lactose or corn starch, each a conventional excipient, is used.

Claims

- (1) A composition which consists essentially of a compound belonging to the vitamin B group and having a solubility in water of not more than 5% and mannitol.
- (2) A composition as claimed in Claim 1, wherein the compound belonging to the vitamin B group has a solubility in water of not more than 3%.
- (3) A composition as claimed in Claim 1, wherein the compound belonging to the vitamin B group has a solubility in water of not more than 1%.
- (4) A composition as claimed in any of Claims 1 to 3, wherein the compound belonging to the vitamin B group and having a solubility in water of not more than 5% is folic acid or vitamin B₂.
- (5) A composition as claimed in any of Claims 1 to 4, said composition being in the form of a powder.
- (6) A composition as claimed in any of Claims 1 to 5, wherein the content of the compound belonging to the vitamin B group and having a solubility in water of not more than 5% is within the range of 100 to 5,000 parts by weight per 100 parts by weight of mannitol.
- (7) A composition as claimed in any of Claims 1 to 5, wherein the content of the compound belonging to the vitamin B group and having a solubility in water of not more than 5% is within the range of 200 to 3,000 parts by weight per 100 parts by weight of mannitol.
- (8) A composition as claimed in any of Claims 1 to 5, wherein the content of the compound belonging to the vitamin B group and having a solubility in water of not more than 5% is within the range of 400 to 2,000 parts by weight per 100 parts by weight of mannitol.
- (9) A composition as claimed in any of Claims 1 to 8, as obtained by suspending, in an aqueous solution of mannitol, a compound belonging to the vitamin B group and having a solubility in water of not more than 5% and subjecting the resulting suspension to spray drying.
- (10) A composition as claimed in Claim 9, wherein the compound belonging to the vitamin B group and having a solubility in water of not more than 5% is folic acid or vitamin B₂.
- (11) A method of producing a composition consisting essentially of a compound belonging to the vitamin B group and mannitol which comprises suspending, in an aqueous solution of mannitol, a compound belonging to the vitamin B group and having a solubility in water of not more than 5% and subjecting the resulting suspension to spray drying.
- (12) A method of production as claimed in Claim 11, wherein the compound belonging to the vitamin B group and having a solubility in water of not more than 5% is folic acid or vitamin B₂.
- (13) A composition as claimed in any of Claims 1 to 10, said composition being coated with a wax, an oil or fat.
- (14) A composition as claimed in Claim 13, wherein a wax is carnauba wax.
- (15) A composition as claimed in Claim 13 or 14, wherein a wax, an oil or fat is used in an amount within the range of 0.1 to 50% by weight based on said composition.
- (16) A composition as claimed in Claim 13 or 14, wherein a wax, an oil or fat is used in an amount within the range of 5 to 30% by weight based on said composition.



European Patent
Office

EUROPEAN SEARCH REPORT

Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 90303130.0
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.)
X	US - A - 3 145 146 (H.A.LIEBERMANN et al.) * Claims 1,3,4,8; examples 12,15,18,19 * --	1-5	A 61 K 9/14 A 61 K 31/505 A 61 K 31/525 A 61 K 47/26
X	US - A - 3 384 546 (B.T.PALERMO) * Claims 1,6; examples 1,2 * --	1-5	
X	US - A - 3 446 899 (A.CAVALLI, L.MAGID) * Claims 1-4; column 2, line 69 - column 3, line 1; example 10b * --	1-5	
Y	GB - A - 2 145 331 (R.P.SCHERER PTY LTD) * Claims 1,6,7; example 6; page 2, lines 7-10; page 1, lines 61-63 * --	1-6	
Y	US - A - 3 721 725 (A.R.BRIGGS, T.J.MAXWELL) * Claims 1,2 * --	1-6	TECHNICAL FIELDS SEARCHED (Int. Cl.) A 61 K 9/00 A 61 K 31/00 A 61 K 47/00
A	PATENT ABSTRACTS OF JAPAN, unexamined applications, C field, vol. 4, no. 85, June 18, 1980 THE PATENT OFFICE JAPANESE GOVERNMENT page 71 C 15 * Kokai-no. 55-49 313 (RIKEN VITAMIN OIL K.K.) * --	1-5, 11-13	
A	PATENT ABSTRACTS OF JAPAN, unexamined applications, C field, vol. 4, no. 190, December 26, 1980 THE PATENT OFFICE JAPANESE	1, 11	
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 17-05-1990	Examiner MAZZUCCO
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date O : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



-2-

EP 90303130.0

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.)														
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim															
A	GOVERNMENT page 90 C 37 * Kokai-no. 55-129 220 (YAMANOUCHI SEIYAKU K.K.) * -- PATENT ABSTRACTS OF JAPAN, unexamined applications, C section, vol. 2, no. 46, March 28, 1978 THE PATENT OFFICE JAPANESE GOVERNMENT page 5098 C 77 * Kokai-no. 52-156 916 (YAMANOUCHI SEIYAKU K.K.) * -----	1,11	TECHNICAL FIELDS SEARCHED (Int. Cl.)														
	The present search report has been drawn up for all claims																
Place of search VIENNA		Date of completion of the search 17-05-1990	Examiner MAZZUCCO														
<table border="0"><tr><td>CATEGORY OF CITED DOCUMENTS</td><td>T : theory or principle underlying the invention</td></tr><tr><td>X : particularly relevant if taken alone</td><td>E : earlier patent document, but published on, or</td></tr><tr><td>Y : particularly relevant if combined with another</td><td>after the filing date</td></tr><tr><td>document of the same category</td><td>O : document cited in the application</td></tr><tr><td>A : technological background</td><td>L : document cited for other reasons</td></tr><tr><td>O : non-written disclosure</td><td>& : member of the same patent family, corresponding</td></tr><tr><td>P : intermediate document</td><td>document</td></tr></table>				CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention	X : particularly relevant if taken alone	E : earlier patent document, but published on, or	Y : particularly relevant if combined with another	after the filing date	document of the same category	O : document cited in the application	A : technological background	L : document cited for other reasons	O : non-written disclosure	& : member of the same patent family, corresponding	P : intermediate document	document
CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention																
X : particularly relevant if taken alone	E : earlier patent document, but published on, or																
Y : particularly relevant if combined with another	after the filing date																
document of the same category	O : document cited in the application																
A : technological background	L : document cited for other reasons																
O : non-written disclosure	& : member of the same patent family, corresponding																
P : intermediate document	document																